Shaden Alhazmi

Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects.

Hanan Makhdoum, Abeer Surihan Alharbi, Shaden Alhazmi, Ahlam Alrehaili et autres

Vascular endothelial growth factor (VEGF) is an important driver of abnormal retinal neovascularization and increased vascular permeability. VEGF overexpression is associated with a number of retinal conditions, such as diabetic macular edema (DME), and neovascular age-related macular degeneration (nAMD). Anti-VEGF treatments have …

sa (code pays fourni par la source)

Efficacy of Dupilumab in Treating Trachyonychia and Other Nail Dystrophies: A Systematic Review of Case Reports

Shaden Alhazmi, Shatha Y. Albyali, Rawan Alanazi, Baraa Alhejaili et autres

Trachyonychia and related nail dystrophies are often associated with inflammatory skin diseases such as atopic dermatitis, psoriasis, and alopecia areata. Management remains difficult, as standard therapies frequently yield limited benefit. Dupilumab, an IL-4Rα antagonist, is effective for Th2-driven conditions, but its role …

bd, sa (code pays fourni par la source)

Baricitinib efficacy and safety for bullous pemphigoid: systematic review and meta-analysis

Shaden Alhazmi, Mariyah Alyahya, Ohud A Alnaji, Nada Alshahrani et autres

Bullous pemphigoid (BP) is considered a chronic autoimmune blistering disorder that affects the elderly and is often associated with long-term immunosuppressive management. Traditional treatment of BP included the use of corticosteroids and immunosuppressants, which can be associated with significant side effects and …